Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 736 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR How to Be Brave When Your Parent Has Cancer: A Kid’s... April 13, 2021 Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Inspiring the next generation of cancer researchers November 16, 2021 Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 Load more HOT NEWS Twins Born 15 Minutes Apart Have Birthdays In Different Years EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment... FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix
